Loading
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Previous close
$0.2849
+$0.0049 · +1.75%
Pre-market
$0.288
+$0.0031 · +1.09%
Oct 9, 6:56 AM ET
Regular session · ET · Market data may be delayed.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Day range
Current $0.2849
52-week range
Current $0.2849
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
22
Expensive
Sentiment
53
Mixed
Risk
50
Elevated Risk
Momentum
29
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
Day range
Current $0.2849
52-week range
Current $0.2849
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Revenue | 1.19M USD | 1.27M USD | 1.35M USD | 911K USD | 397K USD |
| Cost of goods sold | 834K USD | 652K USD | 612K USD | 1.07M USD | 203K USD |
| Gross profit | 352K USD | 619K USD | 733K USD | −158K USD | 194K USD |
| Research and development | 5.19M USD | 3.66M USD | 3.77M USD | 3.46M USD | 2.33M USD |
| Selling, general, and administrative | 5.36M USD | 4.41M USD | 6.76M USD | 7.95M USD | 13.29M USD |
| Operating expenses | 10.56M USD | 8.07M USD | 10.53M USD | 11.41M USD | 15.62M USD |
| Depreciation and amortization | 58K USD | 618K USD | 637K USD | 657K USD | 651K USD |
| Operating income | −10.2M USD | −7.45M USD | −9.8M USD | −11.57M USD | −15.43M USD |
| Net income | −6.55M USD | −7.12M USD | −13M USD | −11.51M USD | −15.02M USD |
Company facts updated Oct 9, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Apr 19, 2013 | 1:10 | — | — |
Effective Apr 19, 2013
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
